{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T16:39:41Z","timestamp":1758040781925,"version":"3.44.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005227","name":"Centers for Medicare and Medicaid Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005227","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.amjmed.2023.07.003","type":"journal-article","created":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T01:42:30Z","timestamp":1689385350000},"page":"1018-1025.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk of Severe COVID-19 in Prevalent Users of Alpha-1 Adrenergic Receptor Antagonists: A National Case-Control Study of Medicare Beneficiaries"],"prefix":"10.1016","volume":"136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7469-4047","authenticated-orcid":false,"given":"David J.","family":"Graham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hector S.","family":"Izurieta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armen","family":"Avagyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Wiederhorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew D.","family":"Mosholder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueqin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanlai","family":"Shangguan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huei-Ting","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinci","family":"Pennap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander T.","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Wernecke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas E.","family":"MaCurdy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A.","family":"Kelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Forshee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.amjmed.2023.07.003_bib0001","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1172\/JCI137244","article-title":"Clinical and immunological features of severe and moderate coronavirus disease 2019","volume":"130","author":"Chen","year":"2020","journal-title":"J Clin Invest."},{"key":"10.1016\/j.amjmed.2023.07.003_bib0002","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.amjmed.2023.07.003_bib0003","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.amjmed.2023.07.003_bib0004","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet."},{"issue":"7","key":"10.1016\/j.amjmed.2023.07.003_bib0005","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1172\/JCI139642","article-title":"Preventing cytokine storm syndrome in COVID-19 using \u03b1-1 adrenergic receptor antagonists","volume":"130","author":"Konig","year":"2020","journal-title":"J Clin Invest."},{"issue":"7735","key":"10.1016\/j.amjmed.2023.07.003_bib0006","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-018-0774-y","article-title":"Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome","volume":"564","author":"Staedtke","year":"2018","journal-title":"Nature."},{"key":"10.1016\/j.amjmed.2023.07.003_bib0007","doi-asserted-by":"crossref","first-page":"e61700","DOI":"10.7554\/eLife.61700","article-title":"Alpha-1 adrenergic receptor antagonists to prevent hyperinflammation and death from lower respiratory tract infection","volume":"10","author":"Koenecke","year":"2021","journal-title":"Elife."},{"issue":"2","key":"10.1016\/j.amjmed.2023.07.003_bib0008","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.37053","article-title":"Association of \u03b1-1blocker receipt with 30-day mortality and risk of intensive care unit admission among adults hospitalized with influenza or pneumonia in Denmark","volume":"4","author":"Thomsen","year":"2021","journal-title":"JAMA Netw Open."},{"key":"10.1016\/j.amjmed.2023.07.003_bib0009","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1532-5415.1999.tb01603.x","article-title":"Assessment and control for confounding by indication in observational studies","volume":"47","author":"Psaty","year":"1999","journal-title":"J Am Geriatr Soc."},{"issue":"1","key":"10.1016\/j.amjmed.2023.07.003_bib0010","doi-asserted-by":"crossref","first-page":"5749","DOI":"10.1038\/s41467-020-19478-2","article-title":"Collider bias undermines our understanding of COVID-19 disease risk and severity","volume":"11","author":"Griffith","year":"2020","journal-title":"Nat Commun."},{"issue":"13","key":"10.1016\/j.amjmed.2023.07.003_bib0011","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1001\/jama.2022.1820","article-title":"Collider bias","volume":"327","author":"Holmberg","year":"2022","journal-title":"JAMA."},{"key":"10.1016\/j.amjmed.2023.07.003_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.637647","article-title":"The association between alpha-1 adrenergic receptor antagonists and in-hospital mortality from COVID-19","volume":"8","author":"Rose","year":"2021","journal-title":"Front Med."},{"key":"10.1016\/j.amjmed.2023.07.003_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.945592","article-title":"International cohort study indicates no association between alpha-1 blockers and susceptibility to COVID-19 in benign prostatic hyperplasia patients","volume":"13","author":"Nishimura","year":"2022","journal-title":"Front Pharmacol."},{"issue":"12","key":"10.1016\/j.amjmed.2023.07.003_bib0014","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1136\/oem.2004.014472","article-title":"An incidence density sampling program for nested case-control analyses","volume":"61","author":"Richardson","year":"2004","journal-title":"Occup Environ Med."},{"issue":"7","key":"10.1016\/j.amjmed.2023.07.003_bib0015","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/MLR.0000000000000729","article-title":"Development of a claims-based frailty indicator anchored to a well-established frailty phenotype","volume":"55","author":"Segal","year":"2017","journal-title":"Med Care."},{"issue":"6","key":"10.1016\/j.amjmed.2023.07.003_bib0016","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1093\/aje\/kwx257","article-title":"External validation of the claims-based frailty index in the National Health and Aging Trends Study cohort","volume":"186","author":"Segal","year":"2017","journal-title":"Am J Epidemiol."},{"issue":"6","key":"10.1016\/j.amjmed.2023.07.003_bib0017","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol."},{"issue":"11","key":"10.1016\/j.amjmed.2023.07.003_bib0018","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care."},{"issue":"1","key":"10.1016\/j.amjmed.2023.07.003_bib0019","first-page":"15","article-title":"Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization","volume":"14","author":"Young","year":"2008","journal-title":"Am J Manag Care."},{"issue":"11","key":"10.1016\/j.amjmed.2023.07.003_bib0020","first-page":"721","article-title":"Validating the adapted diabetes complications severity index in claims data","volume":"18","author":"Chang","year":"2012","journal-title":"Am J Manag Care."},{"key":"10.1016\/j.amjmed.2023.07.003_bib0021","series-title":"Goodman & Gilman\u2019s: The Pharmacologic Basis of Therapeutics. 13th ed","article-title":"Adrenergic agonists and antagonists","author":"Westfall","year":"2021"},{"issue":"24","key":"10.1016\/j.amjmed.2023.07.003_bib0022","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1001\/jama.2020.20323","article-title":"Uptake and accuracy of the diagnosis code for COVID-19 among US hospitalizations","volume":"324","author":"Kadri","year":"2020","journal-title":"JAMA."},{"key":"10.1016\/j.amjmed.2023.07.003_bib0023","doi-asserted-by":"crossref","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med."},{"key":"10.1016\/j.amjmed.2023.07.003_bib0024","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1002\/sim.2790","article-title":"Analysis of matched case\u2013control data with multiple ordered disease states: possible choices and comparisons","volume":"26","author":"Mukherjee","year":"2007","journal-title":"Stat Med."},{"key":"10.1016\/j.amjmed.2023.07.003_bib0025","doi-asserted-by":"crossref","first-page":"e00602","DOI":"10.1002\/prp2.602","article-title":"The affinity and selectivity of \u03b1-adrenoceptor antagonists, antidepressants, and antipsychotics for the human \u03b11A, \u03b11B, and \u03b11D-adrenoceptors","author":"Proudman","year":"2020","journal-title":"Pharmacol Res Perspect."},{"issue":"8","key":"10.1016\/j.amjmed.2023.07.003_bib0026","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.2174\/1570159X15666170630163616","article-title":"Antipsychotic drugs: from receptor-binding profiles to metabolic side effects","volume":"16","author":"Siafis","year":"2018","journal-title":"Curr Neuropharmacol."},{"issue":"17","key":"10.1016\/j.amjmed.2023.07.003_bib0027","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1002\/sim.2790","article-title":"Analysis of matched case-control data with multiple ordered disease states: possible choices and comparisons","volume":"26","author":"Mukherjee","year":"2007","journal-title":"Stat Med."},{"issue":"24","key":"10.1016\/j.amjmed.2023.07.003_bib0028","doi-asserted-by":"crossref","first-page":"4950","DOI":"10.1002\/sim.3325","article-title":"Fitting stratified proportional odds models by amalgamating conditional likelihoods","volume":"27","author":"Mukherjee","year":"2008","journal-title":"Stat Med."},{"key":"10.1016\/j.amjmed.2023.07.003_bib0029","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/pds.5407","article-title":"Core concepts in pharmacoepidemiology: confounding by indication and the role of active comparators","volume":"31","author":"Sendor","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"16","key":"10.1016\/j.amjmed.2023.07.003_bib0030","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1007\/s11606-022-07701-3","article-title":"Medications associated with lower mortality in a SARS-CoV-2 positive cohort of 26,508 veterans","volume":"37","author":"Hunt","year":"2022","journal-title":"J Gen Intern Med."},{"issue":"4","key":"10.1016\/j.amjmed.2023.07.003_bib0031","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmaco-epidemiology","volume":"167","author":"Suissa","year":"2008","journal-title":"Am J Epidemiol."}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934323004370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934323004370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:31:00Z","timestamp":1757583060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934323004370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0002934323004370"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2023.07.003","relation":{},"ISSN":["0002-9343"],"issn-type":[{"type":"print","value":"0002-9343"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of Severe COVID-19 in Prevalent Users of Alpha-1 Adrenergic Receptor Antagonists: A National Case-Control Study of Medicare Beneficiaries","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2023.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}